In ovarian cancer, Gallardo-Rincón et al. (2020) [61] identified germline BRCA2 variants in approximately one-third of mutation-positive patients, highlighting clinically relevant differences in outcome compared to BRCA1 carriers. The gene discussed is BRCA1; the disease is ovarian cancer.